Concepedia

Author

Chadi Nabhan

Caris Life Sciences (United States)ORCID

Also Known As

C Nabhan, C. Nabhan, Chadi Nabhan, Chadi Nabhan (3843511), Nabhan, Chadi

280

Publications

2.3K

Citations

25

H-Index

62

Concepts

All Affiliations

Caris Life Sciences (United States)University of ChicagoAdvocate Lutheran General HospitalThe Barbara Ann Karmanos Cancer InstituteNorthwestern University
CN

About

Chadi Nabhan is an author at Caris Life Sciences (United States) specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

14

16

639

2

Health Sciences

4

4

169

3

Cell Biology

2

2

52

4

Business

1

1

15

5

Public Health

1

1

42

Chadi Nabhan

×

38

Publications

1.3K

Citations

22

H-Index

YearCitations

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer

Russell Z. Szmulewitz, Cody J. Peer, Abiola Ibraheem,

Journal of Clinical Oncology

2018

177

Impact of oncogene rearrangement patterns on outcomes in patients with double‐hit non‐Hodgkin lymphoma

Daniel J. Landsburg, Adam M. Petrich, Jeremy S. Abramson,

Cancer

2015

83

Real-world Evidence—What Does It Really Mean?

Chadi Nabhan, Andrew J. Klink, Vinay Prasad

JAMA Oncology

2019

57

A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer

Kimberly Kruczek, Megan Ratterman, Kathy Tolzien,

British Journal of Cancer

2013

54

Erlotinib Has Moderate Single-agent Activity in Chemotherapy-naïve Castration-resistant Prostate Cancer: Final Results of a Phase II Trial

Chadi Nabhan, Timothy M. Lestingi, Ángel Gálvez,

Urology

2009

54

Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old

Simrit Parmar, Lynn M. Rundhaugen, Larry Boehlke,

Leukemia Research

2004

53

A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma

Andrew M. Evens, Kenneth R. Carson, Jill Kolesar,

Annals of Oncology

2013

52

Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma

Andreas Seeber, Kai Zimmer, Florian Kocher,

ESMO Open

2020

51

Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type

Jim Abraham, Amy B. Heimberger, John L. Marshall,

Translational Oncology

2021

45

Real-World Evidence and Randomized Studies in the Precision Oncology Era: The Right Balance

Bishal Gyawali, Sandeep Parsad, Bruce A. Feinberg,

JCO Precision Oncology

2017

42

Page 1